Gabis 2019.

Methods	12‐week cross‐over trial of donepezil versus placebo
Participants	Inclusion criteria: clinical diagnosis of ASD or PDD‐NOS aged 10‐18 years parental consent provided to participate in the study Exclusion criteria: any infectious disease, chromosomal abnormalities, metabolic disorders, neurological conditions "use of psychostimulants, anti‐depressants, neuroleptics or anti‐convulsive agents within the past month" brain damage; or significant head injury Location/setting: Israel Sample size: target of 84 participants Number randomised: 60 in total (donepezil + choline (29) or placebo (31)) Number analysed: 48 (intervention (23), placebo (25)) Number and reason for dropouts: 14 were reported to have dropped out ("Six subjects dropped out after the first assessment due to lack of compliance, and three additional subjects subsequently failed to attend follow‐up for the second assessment. Three subjects (one in the placebo group and two in the treatment group) were excluded during treatment due to side effects"). Gender: not reported Mean age: not reported IQ: not reported Concomitant medications: not reported Previous medications: not reported
Interventions	Intervention (donepezil + choline) for 12 weeks: maximum donepezil 5 mg/day taken once daily, choline 250 mg/day (children up to 40 kg) or 500 mg/day (children 40 kg and over) Comparator (placebo) for 12 weeks: equivalent placebo
Outcomes	Primary outcomes: AEs Secondary outcomes: none reported Timing of outcome assessments: baseline, weeks 4, 8 and 12 (endpoint)
Notes	Study start date: March 2010 Study end date: December 2017 Source of funding: not reported Conflicts of interest: not reported